Unicycive Therapeutics Securities Class Action Lawsuit Affects Investors

Strategic Insights -

Purchasers of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025, may be entitled to compensation, according to a class action lawsuit. The lawsuit alleges that defendants made false and/or misleading statements about the company's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbunate New Drug Application.

Key Takeaways:

  • The lawsuit covers purchases of Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive.
  • The lead plaintiff deadline is October 14, 2025, and investors may file to join the Unicycive class action.
  • A lead plaintiff is a representative party directing the litigation on behalf of other class members.
  • The Rosen Law Firm, P.A. represents investors throughout the globe, focusing on securities class actions and shareholder derivative litigation.
  • The firm has a history of significant recoveries for investors, including a $438 million settlement in 2019.
  • Laurence Rosen, Esq., a founding partner of the Rosen Law Firm, was named a 2020 Law360 Titan of Plaintiffs' Bar.

Statistics:

  • The lawsuit claims damages for investors who purchased Unicycive securities during the Class Period.
  • The Class Period ran from March 29, 2024 to June 27, 2025, both dates inclusive.
  • The Rosen Law Firm has a history of high-profile settlements, including a $438 million recovery in 2019.

Sources:

  • Newsfile Corp., October 14, 2025 - "Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investor Lawsuit - Unicycive Shareholders Encouraged to C"
  • The Rosen Law Firm, P.A.
  • Law360 (2020) - "2020 Titans of Plaintiffs' Bar: Laurence Rosen"